

Resources for the 3Rs

Replacement Refinement Reduction



OLAW Online Seminar



Resources for the 3Rs

Replacement Refinement Reduction

Brian Haugen, PhD, NIH OER
Alissa Resch, PhD, Coriell Institute
Patricia Brown, VMD, MS, DACLAM, NIH OLAW



OLAW Online Webinar

3Rs

"In 1959, W.M.S. Russell and R.L. Burch published a practical strategy of replacement, refinement, and reduction—referred to as the 3Rs—for researchers to apply when considering experimental design in laboratory animal research.

Over the years, the 3 Rs have become an internationally accepted approach for researchers to apply when deciding to use animals in research and in designing humane animal research studies."



Replacement

"Replacement refers to methods that avoid using animals.

The term includes absolute replacements (i.e., replacing animals with inanimate systems such as computer programs) as well as

relative replacements (i.e., replacing animals such as vertebrates with animals that are lower on the phylogenetic scale)."



Refinement

"Refinement refers to modifications of husbandry or experimental procedures to enhance animal well-being and minimize or eliminate pain and distress.

While institutions and investigators should take all reasonable measures to eliminate pain and distress through refinement, IACUCs should understand that with some types of studies there may be either unforeseen or intended experimental outcomes that produce pain.

These outcomes may or may not be eliminated based on the goals of the study."



Reduction

Reduction involves strategies for obtaining comparable levels of information from the use of fewer animals or for maximizing the information obtained from a given number of animals (without increasing pain or distress) so that in the long run fewer animals are needed to acquire the same scientific information.



IACUC Review and the 3Rs

PHS Policy IV.C.1.

http://grants.nih.gov/grants/olaw/references/phspol.htm


- US Government Principle III
- US Government Principle IV

http://grants.nih.gov/grants/olaw/references/phspol.htm#USGovPrinciples





OER Office of Data Analysis Tools and Systems



NIH Research Portfolio Online Reporting Tools

<u>http://report.nih.gov</u> <u>http://projectreporter.nih.gov</u>

Brian Haugen, Ph.D.

NIH Office of Extramural Research



Goals of RePORT Program

OER Office of Data Analysis Tools and Systems

- RePORT is the NIH's commitment to the highest level of public accountability in carrying out its scientific missions.
- The Research Portfolio Online Reporting Tools website provides access to reports, data, and analyses of NIH research activities, including expenditures and the results of supported research.
- Our goals are to
 - Gather all NIH data and reports
 - Make these data easily accessible to the public
 - Highlight the links between NIH funding and research results and products



Institute/Center: Fiscal Year:

ACTIVE

2013

2012

ALL

NCI

NEL



OER Office of Data Analysis Tools and Systems

results of NIH supported research.



public accountability. To that end, the Research Portfolio Online Reporting Tools provides access to

reports, data, and analyses of NIH research activities, including information on NIH expenditures and the

Principal Investigator:

(Last Name, First Name)

Organization



RePORT Tutorials

U.S. Department of Health & Human Services



in addition to carrying out its scie nublic accountability. To that and


RePORT TUTORIALS

Home > About RePORT > RePORT Tutorials



RePORT Tutorials


http://report.nih.gov/tutorial/



• RePORTER, = Expenditures and Results


- Information is included from
 - NIH, intramural and extramural for the past 25 years
 - Patents, publications, and other research outcomes
 - Projects supported by other components of HHS
 - ACF, AHRQ, CDC, FDA
 - Projects supported by the VA








RePORTER--Text Search







RePORTER--Text Search








RePORTER—Search Search


OER Office of Data Analysis Tools and Systems







RePORTER—Advanced Text Search





Search Results Back to Query Form Save Query Share Query Export All Projects PROJECTS PUBLICATIONS PATENTS CLINICAL STUDIES DATA & VISUALIZE MAP There were 139 results matching your search criteria. Show/Hide Search Criteria * Records per page Click on the column header to sort the results 123456 Page 1 of 6 Next Last T: Application Type; Act: Activity Code; Project: Admin IC, Serial No.; Year: Support Year/Supplement/Amendment Funding FY Total Cost Contact PI/ Similar T Act Project Year Sub # Project Title Admin IC Organization **Project Leader** IC by IC **Projects** MIDWEST RESEARCH 273201100001C-3-0-2 HIGH THROUGHPUT SCREENING ALGAIER, CLARK 2013 **NIEHS** NIEHS \$521,169 INSTITUTE ROLE OF I Project 5 of 139 TOXICANT 1 R01 ES024915 01 IN DNA ME DESCRIPTION DETAILS RESULTS HISTORY SUBPROJECTS SIMILAR PROJECTS NEARBY PROJECTS BETA LINKS & NEWS AND MORE & Project Number: 5R21CA187516-02 Contact PI / Project Leader: AMATRUDA, JAMES F DISTRIBU A NOVEL FUNCTIONAL GENOMIC PIPELINE FOR TARGET IDENTIFICATION IN Awardee Organization: UT SOUTHWESTERN MEDICAL CENTER P01 ES021921 04 5582 HUMAN HE MARINE P Abstract Text: DESCRIPTION (provided by applicant): The long-term goal of this work is to improve outcomes in Ewing Sarcoma, the most lethal bone tumor of children. Ewing Sarcoma Family Tumors (ESFT) are the second most common bone and soft tissue cancer afflicting children, adolescents, and young adults. ESFT are characterized by a chromosomal STRATEGI translocation resulting in a fusion between EWS and a member of the ETS family of transcription factors, most commonly FLI1. ESFT are treated with intensive chemotherapy, 5 R13 HD075578 03 ZEBRAFIS radiation, and surgery, yet more than half of patients die of disease within five years of diagnosis, while survivors often suffer long-term deleterious effects of treatment. An immediate need exists for the development of effective and targeted therapies with decreased toxicity. Unfortunately, we still have a limited understanding of the molecular mechanisms of ESFT tumorigenesis, which has greatly impeded the identification of improved therapies. Our preliminary data indicate that recurrent areas of chromosomal gain and loss occur in Ewing Sarcoma, suggesting that amplification or deletion of cooperating genes in these recurring regions facilitate cell transformation by EWS-FLI1. A NOVEL F Identification and validation of these cooperating genes is essential for the development of new therapies, because strategies to target EWS-FLI1 itself have not to date been 5 R21 CA187516 02 PIPELINE successful. We previously developed a zebrafish model of ESFT that recapitulates key features of the human disease. We will now use the fish model for high-throughput functional genomic assays to validate promising candidate EWS-FL11 effector genes emerging from our high- resolution genomic analyses of human ESFT. We will further IDENTIFIC capitalize on this assay by conducting small- molecule screens to identify lead compounds that act as inhibitors of EWS-FLI1-mediated cellular transformation. To achieve this ANALYSIS goal we will 1) identify critical EWS-FLI1 effectors though high-resolution genomic analysis of tumors; 2) use zebrafish in vivo models of EWS-FLI1 activity to validate candidate ESFT effectors identified in genomic copy number analyses; and 3) identify small molecules capable of inhibiting EWS-FLI1 function in the zebrafish model At the completion of 5 R21 GM110184 02 VARIANTS this study, we will have demonstrated the effectiveness of a novel genomic pipeline for discovery and functional analysis of cooperating genes in translocation positive sarcomas. DISEASES This novel pipeline will take advantage of our combined expertise in copy number analysis and comparative oncology using zebrafish models. This new pipeline and its novel approach will lead to the rapid testing and introduction of new therapeutic agents for sarcomas, one of the most deadly types of cancer in children and adults. FUNCTION SARCOMA PROTEINS EVISITEIT AND ALOWA, WILLOW 5 P20 GM103638 04 7862 KANSAS LAWRENCE EWS IN ZEBRAFISH ADULT AND TRANSGENERATIONAL UNIVERSITY OF 5 K01 OD010462 03 TOXICITY DUE TO DEVELOPMENTAL BAKER, TRACIE R. 2015 OD OD \$131,466 WISCONSIN-MADISON TCDD EXPOSURE NATIONAL INSTITUTE OFFICE OF LABORATORY ANIMAL ZIG AA000600 06 BARNES, ANDREA ON ALCOHOL ABUSE 2014 NIAAA NIAAA \$3,807,039 SCIENCE AND ALCOHOLISM

Search Results Back to Query Form Share Query Save Query Export All Projects **PUBLICATIONS** 2 CLINICAL STUDIES DATA & VISUALIZE MAP NEWS & MORE IS ROJECTS There were 3154 publications supported by 3224 Active Projects. Show/Hide Search Criteria ~ Records per page 25 Click on the column header to sort the results 1 2 3 4 ... 127 128 129 1 of 129 Next Last Core Project Similar Cited Title (Link to full-text in PubMed Central) Journal (Link to PubMed abstract) Authors Number Publications By vioural brain research 2015 Sen 15: 201 R24OD010998 The common neur innn neurophilia is ass Pub Med.gov 34 PubMed **‡** response habitua US National Library of Medicine Advanced rerio): Implication National Institutes of Health organism. Abstract + Send to: + Cutting Edge: He P30CA047904 inna Expansion and C J Immunol. 2015 Sep 15;195(6):2524-8. doi: 10.4049/jimmunol.1501231. Epub 2015 Aug 14. 4 Other supporting Depletion Requir projects Cutting Edge: Hematopoietic Stem Cell Expansion and Common Lymphoid Progenitor Depletion Require Autonomous TLF Hematopoietic-Derived, Cell-Autonomous TLR4 in a Model of Chronic Endotoxin. Endotoxin. Liu A1, Wang Y1, Ding Y2, Baez I3, Payne KJ3, Borghesi L4. Oral and intraver Author information P30CA047904 4 fluoro-2'-deoxycy Other supporting Abstract monkeys and hu Hematopoietic stem and progenitors cells (HSPCs) are activated through TLR4 in vitro. However, it remains unclear whether in vivo TLR4 sensing by projects HSPCs occurs directly or via other cell intermediates. In this study, we examined the cellular mechanisms underlying murine hematopoietic stern cell (HSC) expansion and common lymphoid progenitor (CLP) depletion in a model of chronic low-dose LPS. Using adoptive-transfer approaches, we show that HSC and CLP sensitivity to chronic LPS depends on hematopoietic-derived, cell subset-autonomous TLR4. Like murine progenitors, human P30CA047904 Posttraumatic str HSPCs are activated by TLR4 in vitro. Using humanized mice, a preclinical model relevant to human physiology, we show that persistent endotoxin Innni newly diagnosed increases the frequency of Ki-67(+) HSCs and severely depletes CLPs and B precursors. Together, our findings show that murine HSPCs directly Other supporting cancer and their respond to endotoxin in vivo and that persistent LPS, a feature of several diseases of global health significance, impairs human lymphopoiesis. projects Copyright @ 2015 by The American Association of Immunologists, Inc. PMID: 26276875 [PubMed - in process] PMCID: PMC4561199 [Available on 2016-09-15] P30CA051008 Rechallenging 5-Capecitabine-Ind P30CA047904 Theranostic nanoemulsions for macrophage Clinical immunology (Orlando, Fla.), 2015 Sep; Patel, Sravan Kumar, Beaino, Wissam; Anderson, M COX-2 inhibition in a murine inflammation 160 (1):59-70 Carolyn J; Janjic, Jelena M model.

Cancer immunology, immunotherapy; Cll. 2015 Mony, Jyothi Thyagabhayan; Zhang, Lixin; Ma,

Tianzhou: Grabosch, Shannon: Tirodkar, Tejas S:

P30CA047904

Anti-PD-L1 prolongs survival and triggers T cell

but not humoral anti-tumor immune responses in Sep. 64 (9):1095-108

Search Results

2

ROJECTS

Back to Query Form

Save Query

Share Query

Export | All Projects

PATENTS **PUBLICATIO** CLINICAL STUDIES DATA & VISUALIZE MAP NEWS & MORE E

There were 12 connections of patents to projects matching your search criteria. Show/Hide Sea riteria -Click on the column header to sort the results ast > Patent Owner (2) Core Project Number Patent Number **Patent Title** Similar ZIASC006538 7320991 Analogs of thalidomide as potential angiogenesis inhibitors **Projects** ZIASC006538 8716315 Analogs of thalidomide as potential angiogenesis inhibitors 6280956 P30CA047904 Antibodies to bladder cancer nuclear matrix proteins and their use UNIVERSITY OF PITTSBURGH P30CA047904 6951926 Antibody to bladder cancer nuclear matrix protein and its use UNIVERSITY OF PITTSBURGH P30CA047904 7258991 Antibody to bladder cancer nuclear matrix protein and its use UNIVERSITY OF PITTSBURGH P30CA047904 5866535 Bladder nuclear matrix proteins, polynucleotide sequences encoding them, and their UNIVERSITY OF PITTSBURGH use R01DC005987 8232314 Compounds that protect against sensory hair cell death UNIVERSITY OF WASHINGTON P30CA047904 8173366 Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer UNIVERSITY OF PITTSBURGH P30CA047904 8466123 Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer UNIVERSITY OF PITTSBURGH R01DC000200 6136785 Protection from loss of sensory hair cells in the inner ear by administration of insulin-UNIVERSITY OF VIRGINIA like growth factor and platelet derived growth factor 8143252 Tetrahalogenated compounds useful as inhibitors of angiogenesis ZIASC006538 ZIASC006538 7973057 Thalidomide analogs

Download Readers:

About RePORT FAQs Glossary Contact Us Site Map Data Access Policy Accessibility Statement Privacy Statement Disclaimer FOIA Help D

The RePORTER database is available to all public users at http://exporter.nih.gov/. As the data are available for bulk download, the RePORTER system reserves the right to

addresses that fail to adhere to instructions in the system's robots but files or submit requests at a rate that negatively impacts service delivery to other users. RePORTER res

right to terminate any automated query to the RePORTER application that negatively affects service delivery to other users. OFFICE OF LABORATORY ANIMAL ZIG AA000600 06 SCIENCE

BARNES, ANDREA

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIAAA NIAAA

2014

\$3,807,039

Search Results

Core Project Number

P30CA047904

P30CA051008

P30CA051008

P30CA051008

P30CA051008

P30CA051008

P30CA051008

P30CA051008

P30CA047904

P30CA051008

P30CA047904

P30CA051008

P30CA051008

P30CA051008

P30CA051008

P30CA047904

1 ZIG AA000600 06

Back to Query Form

Save Query

Show/Hide Search Criteria -

Export | All Projects

Study Status

COMPLETED

COMPLETED

COMPLETED

COMPLETED

TERMINATED

COMPLETED

RECRUITING

RECRUITING

RECRUITING

WITHDRAWN

NIAAA

ACTIVE. NOT RECRUITING

ACTIVE, NOT RECRUITING

\$3,807,039



There are 24 clinical trial studies for projects matching your search criteria.	
Click on the column header to sort the results	

Triord are E. Control trial broaded for projects indicating your country of	
Click on the column header to sort the results	
CONTRACTOR AND	

NCT01154426

NCT00003297

NCT00003035

NCT00020748

NCT00898937

NCT00416754

NCT00262899

NCT00088829

NCT01935921

NCT02160015

NCT00363428

NCT00685256

NCT01012804

NCT00459238

NCT00287898

NCT01749384

SCIENCE

Study

eria.			
FIEL.			

Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations

Previously Untreated Stage III-IVB Head and Neck Cancer

Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BARNES, ANDREA

Undergoing Surgery for Lung Cancer

Carrying the BRCA1 or BRCA2 Mutation

Cannot Be Removed by Surgery

	AIA & VISUALIZE	MAP	MEMS & MOKE D.	
				-
g your search crite	eria.			

ATA & VISUALIZE	MAP	NEWS & MORE E
de l		

TA & VISUALIZE	MAP	NEWS & MORE E	
ia			

ATA & VISUALIZE	MAP	NEWS & MORE E	
veio			

TA & VISUALIZE	MAP	NEWS & MORE	图

TA & VISUALIZE	MAP	NEWS & MORE &	

S	ATA & VISUALIZE	MAP	NEWS & MORE E

NICAL STUDIES	ATA & VISUALIZE	MAP	NEWS & MORE E	

Stage III or Stage IV Ovarian Cancer

Biopsy of the Breast

Participants

OFFICE OF LABORATORY ANIMAL

ATA & VISUALIZE	MAP	NEWS & MORE	

TA & VISUALIZE	MAP	NEWS & MORE	图

TA & VISUALIZE	MAP	NEWS & MORE E

p	NEWS	& MORE	图

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core

Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic

Lung Rehabilitation in Treating Patients With Chronic Obstructive Pulmonary Disease Who Are

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication

Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or

ON ALCOHOL ABUSE

AND ALCOHOLISM

2014

NIAAA

Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer







PROJECTS ?	PUBLICATIONS	PAT	CLINICAL STUDIES	A
------------	--------------	-----	------------------	---

ClinicalTrials.gov ID

LIN	ICAL	STUDIES	A'

RV	ISLIA	LIZE	MAP

CHARTS

CIRCLES BETA

mmary by

Administering Institute/Center :

Chart . Projects Project Funding Project Publications

Switch to HTML5 Circles

Limit to Top 18 #

COLUMN

cle Visualization

CIRCLES BETA

PATIENTS MUTATION **Patients**

To zoom in on a group, double click it. To zoom out, double click again.

List of Projects	
1ZIASC006538-21	DEVELOPMENT OF ANGIOGENESIS INHIBITORS
5K99CA181500-02	THE ROLE OF THE PROTEIN TYROSINE PHOSPHATASE PRL3 IN LEUKEMIA DEVELOPMENT
1ZIAHG000121-17	MOLECULAR AND CLINICAL STUDIES OF PRIMARY IMMUNODEFICIENCIES
3K08DK101340-02S1	A NOVEL ROLE FOR P53 IN CONGENITAL DISORDERS OF GLYCOSYLATION
1ZIAHG200372-04	GENETICS, PATHOPHYSIOLOGY, AND TREATMENT OF RECESSIVE AUTOINFLAMMATORY DISEASES
1R43AI110285-01	DESTROYING THE HIV-1 PROVIRUS BY UTILIZING COMPONENTS OF THE CRISPR/CAS SYSTEM
5R21AA022396-02	A ZEBRAFISH FETAL ALCOHOL SPECTRUM DISORDER MODEL OF CONGENITAL HEART DEFECTS
1R03AR067507-01A1	NOVEL APPROACHES FOR READ-THROUGH OF NONSENSE MUTATIONS IN COL7A1
5R21GM110184-02	ANALYSIS OF TRNA SYNTHETASE VARIANTS IN THE UNDIAGNOSED DISEASES PROGRAM
5R01CA034590-32	CHEMOKINE SIGNALS IN THE PREMETASTATIC NICHE INHIBIT METASTASIS
1R01HL128135-01	METABOLIC UNDERPINNINGS OF AL AMYLOID CARDIOMYOPATHY
2101BX000820-05A2	CDC-42 AND THE EXOCYST IN CILIOGENESIS AND POLYCYSTIC KIDNEY DISEASE
5P20GM103638-04 (7862)	FUNCTIONAL ANALYSIS OF EWING SARCOMA PROTEINS EWS/FLI1 AND EWS IN ZEBRAFISH
5R01AA018886-05	THE IMPACT OF THE UNFOLDED PROTEIN RESPONSES ON STEATOSIS
5R21CA187516-02	A NOVEL FUNCTIONAL GENOMIC PIPELINE FOR TARGET IDENTIFICATION IN SARCOMA
5R01DC000200-30	GROWTH AND REGENERATION IN THE INNER EAR
5R01CA176746-04	DISCOVERY OF NEW TARGETS AND PATHWAYS FOR T-ALL THERAPY
5R01DK090311-05	ESTROGEN REGULATION OF HEPATIC GROWTH
5R01DK098135-02	FUNCTIONAL AND PHENOTYPIC CHARACTERIZATION OF A NEW FSGS GENE
5R01HL119234-02	HEART FAILURE IN CANCER PATIENTS
5R21CA159203-02	GENETIC MODIFIERS FOR CANCER STEM CELLS IN SECONDARY MDS/AML
5R01CA169117-03	TARGETING FERRITIN IN GLIOBLASTOMA
5R01DK072381-09	KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
5K08DK101340-03	A NOVEL ROLE FOR P53 IN CONGENITAL DISORDERS OF GLYCOSYLATION
5R01DK099551-02	NEW CONGENITAL DISORDERS OF GLYCOSYLATION: THERAPY AND MODELS

Search Results

Back to Query Form Save Query Share Query





Show/Hide Search Criteria -

PATENTS CLINICAL STUDIES DATA & VISUALIZ MAP NEWS & MORE E

Click on a Country/State to view details, Each red circle represents the location of a funded organization that may have one or more projects.

Project Number and Title are linked to project information pages. Congressional District: All Country: UNITED STATES State: CA UTAH Humboldt-Toiyabe National Forest Мар Satellite Sacramento San Francisco Alto San Jose Fresno Death Valley CALIFORNIA National Park Las Vegas San Luis Obispo ARIZON Los Angeles Anaheim Phoenix Long Beach San Mexicali Google Tijuana Map data @2015 Google, INEGI Terms of Use

References to non-NIH products do not constitute an endorsement by the NIH. By viewing the Google Maps API on this web site the user agrees to these <u>TERMS</u> of Service set forth by Google.

If you are not able to view the map, please click here to refresh the page.

PROJECTS

PUBLICATIONS

NATIONAL INSTITUTE

2014

▼ Press Releases 37 Press Releases found.



There are 37 news items citing 15 project(s).

Records per page 25

Click on the column header to sort the results

improve survival

environment


Tiny fish provides giant insight into how organisms adapt to changing

GM104318


Page 1 of 2 Next Last > >>

Grant Number	News				DIE	ECTODY CONTACT	CAREERS INTRANST	Site 6	Search
ES017552	Nanoparticles u	TH	HE SC	RIPI			INSTITUT	THUI IT IS	F W
ES022644	Gene therapy p	ABOUT	RESEARCH	& FACULTY	EDUCATION	CAMPUSES	NEWS	EVENTS	SUPPOR
DK092111	Plant Toxin Cau								
CA051008	Finding liver ca	Overview Press Room		NEWS	RELEASE				
CA051008	Maternal stress model	"In the News" News Releases Publications	+	TSRI Scientists Find Clues to Cancer Drug Failure + LA JOLLA, CA – March 2, 2015 – Cancer patients fear the possibility that					
CA047904	Pitt cancer virol make proteins	Videos		one day their cells might start rendering many diff regimens ineffective. This phenomenon, called me to tumors that defy treatment.	ifferent chemotherapy				
DA031367	Feeling sleepy?						e (TSRI) have published a		
MH102680	Genome-wide s important in ner			pair of s	tudies showing how the respondence characters and the resistance characters are the resistance characters and the resistance characters are the resistance c	TSRI Associate Professor Qin Zhang (right), shown here with Research Associate Sung Chi Lee, was a senior author of bo	own here with ate Sung Chang		
MH102680	Genomewide S Important in Ne			multidru		SRI Associate Profe	cules to inhibit or evade essor Qinghai Zhang, a	studies. (High-res	image)
ES021985	New Insights In Drug Chemothe				at the state of th		ers: a study in the journal or at TSRI with a joint	FOR MORE INF	ORMATION
CA051008	When cancer o						Center, and a paper in ffrey Chang, professor in	Olnghai Zhang Blo	sketch
ES024915	NIEHS Funds 8			The state of the s	San Diego Skaggs S	A STATE OF THE PARTY OF THE PAR		Zhang Lab Website	е
CA047904	Coupling head	and neck cancer :	screening an	20,000				Structure paper Jan 2015	

Se	arcl	h Res	sul	ts					Back to Q	uery Form	Save Query	Share Query
nin o							Back to Qu	ery Fo	orm Sa	ve Query	- Share C	luery
The	ere s				r.nih.gov/Reporter_Viewsh.cfm C3D67598B8961CAA4A01A2FF		11	C	opy Link	OR	Email Link	х
	plication				Project Title	Contact PI/	Organization	FY	Admin IC	Funding IC	FY Total Cost by IC	Similar Projects
0	2732011	100001C-3-0	1-2		HIGH THROUGHPUT SCREENING	ALGAIER CLARK	MIDWEST RESEARCH INSTITUTE	2013	NIEHS	NIEHS	\$521,169	
	1 R01 I	ES024915 0	01		ROLE OF DE NOVO DNMTS IN TOXICANT INDUCED ALTERATIONS IN DNA METHYLATION	ALURU,	WOODS HOLE OCEANOGRAPHIC INSTITUTION	2015	NIEHS	NIEHS	\$478,997	
	5 P01	ES021921 0	04		DISTRIBUTION, PROVENANCE, AND HUMAN HEALTH IMPLICATIONS OF MARINE POLYBROMINATED	ALUWIHARE, LIHINI	UNIVERSITY OF CALIFORNIA SAN DIEGO	2015	NIEHS		\$114,028	
	5 R13 !	HD075578 0	03		STRATEGIC CONFERENCE OF ZEBRAFISH INVESTIGATORS	AMACHER SHARON I	OHIO STATE UNIVERSITY	2015	NICHD	NICHD	\$10,000 \$2,000	
	5 R21	CA187516 0	02		A NOVEL FUNCTIONAL GENOMIC PIPELINE FOR TARGET IDENTIFICATION IN SARCOMA	AMATRUDA, JAMES F et al.	UT SOUTHWESTERN MEDICAL CENTER	2015	NCI	NCI	\$165,530	
	5 R21 (GM110184 0	02		ANALYSIS OF TRNA SYNTHETASE VARIANTS IN THE UNDIAGNOSED DISEASES PROGRAM	ANTONELLIS, ANTHONY	, UNIVERSITY OF MICHIGAN	2015	NIGMS	OD	\$226,475	
	5 P20 C	GM103638 (04	7862	FUNCTIONAL ANALYSIS OF EWING SARCOMA PROTEINS EWS/FLI1 AND EWS IN ZEBRAFISH	AZIINIA MIZIIVI	UNIVERSITY OF KANSAS LAWRENCE	2015	NIGMS		\$184,326	
	<u>5 K01</u>	OD010462 0	03		ADULT AND TRANSGENERATIONAL TOXICITY DUE TO DEVELOPMENTAL TCDD EXPOSURE	BAKER TRACIER	UNIVERSITY OF WISCONSIN-MADISON	2015	OD	OD	\$131,466	
0	1 ZIG	AA000600 0	06		OFFICE OF LABORATORY ANIMAL SCIENCE	BARNES, ANDREA	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2014	NIAAA	NIAAA	\$3,807,039	25



OER Office of Data Analysis Tools and Systems



NIH Research Portfolio Online Reporting Tools My RePORTER





System Health: GREEN Home > RAPORTER > Query Form Login Register RePORTER: NIH RePORTER About RePORTER EXPORTER RePORTER. RSS of Newly Added Projects Manual OER Office of Data Analy QUEF








Thank you for registering to NIH MyRePORTER. A confirmation email has been sent to the email address myemail@somemail

Please click the link in the email to confirm your registration before logging to NIH MyRePORTER.

Please contact RePORT Support Team if you have not received the confirmation email within the next 3 hours.





Required field

OER Office of Data Analysis Tools and Systems

Subject:

NIH MyRePORTER - Your registration request

NIH MyRePORTER

Dear NIH MyRePORTER User:

Thank you for registering with <u>NIH MyRePORTER</u>. To activate your newly created account, Please click on <u>confirm</u> link. Once activated you will be able to save Queries and state A erts.

If you have not requested this change, please contact the RePORT Support Team.


Sincerely,

RePORT Support Team

http://projectReporter.nih.gov



Thank you for the confirmation. Your account is now activated. Please login using your registered email address.







OER Office of Data Analysis Tools and Systems

Home > MyRePORTER > Dashboard

Change Email Address | Delete My Account | Change Password | Logout



Portfolios

You have 0 portfolio(s) in your profile

Name

Description

Created on

Last Revised On




Saved Queries

You have 0 saved queries in your profile

# Title	Notes	Created on	Last Revised On	Action	Project Alert Publication Alert
		No records found.			

No records found.









About RePORTER DATA

FAQ

EXPORTER

RePORTER Manual

RSS of Newly Added Projects



DUERY BROWSEN	IH MATCHMAKER BETA			
SUBMIT QUERY CLEA	AR QUERY	Fiscal Year (FY): Current FY is 2014	Active Projects	SELECT
ESEARCHER AND ORGA	NIZATION			
Principal Investigator (PI) / Project Leader: (Last Name, First Name)	Use '%' for wildcard	City:	Jse '%' for wildcard	
Organization:	Enter several PI/Project Leader names LOOKUP	State:		SELECT
	Please enter at least 3 characters to use Lookup. Contains Begins with Exact	Country:		SELECT
Department:	The state of the s	Congressional District:		SELECT
Organization Type:	SELECT	DUNS Number:		
			R	
EXT SEARCH				
Text Search (Logic):	osteoarthritis	Search in Limit Project search t	o Limit Publication search	to
TEXT SEARCI	Н			
Tavt S	earch (<i>Logic</i>): osteoarthriti		Sear	rch in
		5		Projects
- 6	● <u>And</u>			*
	<u>- 11 - 13 - 13 - 13 - 13 - 13 - 13 - 13</u>			Zublications
	5 <u>or</u>			Publications News





Back to Query Form

Save Query

New Query

Dashboard

Projects

Back to Query Form

PHYSICOCHEMICAL SIGNALING IN

CHIMPANZEE BIOMEDICAL RESEARCH

AGING OSTEOARTHRITIS EFFECT ON

LEUKOCYTE GENE EXPRESSION AND

LEUKOCYTE GENE EXPRESSION AND

REGULATION OF CHONDROCYTES BY

REGULATION OF CHONDROCYTES BY

EXTRACELLULAR MATRIX PROTEIN.

REGULATION OF BONE LOSS BY

REGULATION OF BONE LOSS BY

ARTHRITIS

IL-23/IL-17A AXIS IN INFLAMMATORY

IL-23/IL-17A AXIS IN INFLAMMATORY

EXTRACELLULAR MATRIX PROTEIN

STRUCTURE-FUNCTION OF HUMAN

MENISCAL ATTACHMENTS

GENETIC BIOMARKERS OF OA

INCIDENCE AND PROGRESSION

GENETIC BIOMARKERS OF OA

INCIDENCE AND PROGRESSION

Project Title

OSTEOARTHRITIS

RESOURCE

New Query

Dashboard

\$157,989

\$2,437,039

\$37,555

\$35,680

\$681,007

\$137,334

\$344,336

\$59,459

PROJECTS ?	PI
There were 808 re	esu
Click on the colum	n h

Ollow off the Column field
T: Application Type; Act:

lts T Act Project Year Sub# 5 K24 AR002128 09 5 U42 OD011197 13 3 R01 AR052873 08S1 5 R01 AR052873 08 3 R01 AR054817 05S1

5 F31 AG039975 03

5 R01 AR054817 05

3 R01 AR062173 02S1 5 R01 AR062173 02

Save Query

Contact Pil

Project Leader

AARON, ROY K

ABEE, CHRISTIAN R

ABRAHAM, ADAM

ABRAMSON, STEVEN B

ABRAMSON, STEVEN B

ABRAMSON, STEVEN B

ABRAMSON, STEVEN B

ADAMOPOULOS, IANNIS

ADAMOPOULOS, IANNIS

ELIAS

CHRISTOPHER

NIAMS

OD

NIA

NIAMS

NIAMS

NIAMS

NIAMS

NIAMS

NIAMS



Organization

by IC

NIAMS

OD

NIA

OD

NIAMS

OD

NIAMS

NIAMS

NIAMS



2011

2013

2013

2013

2013

2013

2013





HOSPITAL

UT MD ANDERSON

COLORADO STATE

NEW YORK UNIVERSITY

NEW YORK UNIVERSITY

NEW YORK UNIVERSITY

NEW YORK UNIVERSITY

SCHOOL OF MEDICINE

UNIVERSITY OF

CALIFORNIA DAVIS

SCHOOL OF MEDICINE

SCHOOL OF MEDICINE

SCHOOL OF MEDICINE

CANCER CTR

UNIVERSITY


RHODE ISLAND





New Query Dashboard

Save New Query








Your search criteria have been saved successfully.

Saved Queries







Back to Query Form Back to Search Results Dashboard Print Version

Project Information @

3AR002033-01A1

PREVIOUS Project 13 of 808

NEXT

ih.gov>

DESCRIPTION DETAILS RESULTS HISTORY SUBPROJECTS SIMILAR PROJECTS NEARBY PROJECTS SIMILAR PROJECTS NEARBY PROJECTS SIMILAR PR

Project Number: 1K23AR062099-01A1 Contact PI / Project Leader: SIBILLE, KIMBERLY THERESA

Title: BIOLOGICAL MARKERS OF SYSTEM BURDEN IN SYMPTOMATIC KNEE OA: Awardee Organization: UNIVERSITY OF FLORIDA

A PROSPECTIVE STUDY

Abstract Text:

DESCRIPTION (provided by applicant): osteoarthritis (OA) is a leading cause of pain and functional limitation in the United States. There are significant individual and ethnic group differences in the experience of OA. An improved understanding of factors contributing to the disparities and a biomarker reflecting the variability is needed. The research goals and career development training objectives identified in this K23 Mentored Patient-Oriented Research Career Development Award application have been developed to obtain the training and experience to pursue investigations of the biological interface of chronic pain and psychosocial stress in knee OA. Entitled Biological Markers of System Burden in Symptomatic Knee OA: A Prospective Study, the proposed study expands on current research supported in part through the Basic Behavioral and Social Science Opportunity Network (OppNet) specific to Dr. Sibille's research interests and career ambitions. Additionally, the proposed research aligns with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Long Range Plan for Fiscal Years 2010-2014 and the 2010 NIAMS Roundtable Summary. My career goals are to: 1) excel in an academic medical setting as a clinical/translational pain investigator with expertise in osteoarthritis involved in patient-oriented research and 2) contribute to the research and medical community through scholarship and education with an overall goal of improving the management, functioning, and quality of life for individuals with osteoarthritis and other pain-related conditions. My career development training objectives incorporate activities and experiences pertinent to my research goals and necessary to obtain R01 funding by 2016. Objective 1: Develop a comprehensive knowledge-base in osteoarthritis Objective 2: Broaden skills in multi-modal assessment of pain and functional limitations Objective 3: Increase understanding of genetics and stress-related biological systems Objective 4: Enhance management skills necessary to function as an independent researcher Objective 5: Strengthen skills in clinical/translational research, statistics, and scholarship My career development research and training efforts will be guided by an exceptional mentoring team, Roger Fillingim, Ph.D., Primary Mentor, will provide guidance and oversight in the multi-modal assessment of pain and functional limitations; the integration of biological and psychosocial factors; and my overall career development. Roland Staud, M.D., will oversee the development of a comprehensive knowledge-base in osteoarthritis. Christiaan Leeuwenburgh, Ph.D., Co-Mentor, will provide direction in areas related to metabolic processes, evaluating biological markers, and developing the skills necessary for translational investigation. Taimour Langaee, Ph.D., Co-Mentor, will assist with training and development in the areas of immunology, genetics, and telomere measures. Bruce McEwen, Ph.D., Consultant/Co-Mentor, will direct my training specific to neuroendocrine functioning, the effects of stress on health, and the application of the allostatic load model in the study of knee osteoarthritis. My transition to research independence will also be benefited by

s email only lists up to the first r results.

ontact PI / Project Leader

IBILLE, KIMBERLY
HERESA

You are receiving this email because you have subscribed to receive alerts from the NIH MyRePORTER system. You can change your alerts preferences by logging into the system. If you have not requested these alerts, please contact the RePORT Support Team.

Sincerely,

RePORT Support Team

http://projectreporter.nih.gov




Matchmaker



OER Office of Data Analysis Tools and Systems


MATCHMAKER BETA BROWSE NIH QUERY Use Matchmaker to find similar projects Enter abstracts or other scientific text and Matchmaker will return a list of 100 similar projects from RePORTER. These matches are based on the terms and concepts used in the submitted text. Up to 15,000 characters are permitted. Enter your Text: Terms will be weighted by frequency of appearance in the text above. The process is automated and confidential. The Matchmaker system does not track and store submitted text. CLEAR SUBMIT








Matchmaker Results




5	Match Score	T Act Project Year Sub#	Project Title	Contact PI / Project Leader	Organization	FY	Admin IC	Funding IC	FY Total Cost by IC	Similar Projects
Ó	975	5 F31 DA031559 03	PRENATAL CANNABIS EXPOSURE AND EPIGENETIC MECHANISMS UNDERLYING VULNERABILITY TO	MORRIS, CLAUDIA VARGAS	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	2013	NIDA	NIDA	\$31,762	
۵	935	5 R01 DA033660 03	MULTIGENERATIONAL EPIGENETIC EFFECTS OF CANNABIS EXPOSURE	HURD, YASMIN L	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	2014	NIDA	NIDA	\$445,208	
0	886	5 F30 DA024929 05	BRAIN AND BEHAVIORAL EFFECTS OF PENK GENE MANIPULATION IN RAT NUCLEUS ACCUMBENS	TOMASIEWICZ, HILARIE C	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	2012	NIDA	NIDA	\$46,182	
ō	879	5 R01 DA019350 06	NEURODEVELOPMENTAL EFFECTS OF ADOLESCENT CANNABIS USE	HURD, YASMIN L	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	2008	NIDA	NIDA	\$275,629	
O	869	5 F30 DA024929 03	BRAIN AND BEHAVIORAL EFFECTS OF PENK GENE MANIPULATION IN RAT NUCLEUS ACCUMBENS	TOMASIEWICZ, HILARIE C	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	2010	NIDA	NIDA	\$43,812	
			BRAIN AND BEHAVIORAL EFFECTS	TOMASIEWICZ	ICAHN SCHOOL OF					(780)
0	002	5 F30 DA024929 02	RAT NUCLEUS ACCUMBENS	HILARIE C	SINAL	2009	NIDA	MIDA	\$43,000	

Matchmaker Results





Matchmaker Results





Matchmaker

New Query




Federal RePORTER (Alpha)

http://FederalRePORTER.nih.gov

OER Office of Data Analysis Tools and Systems










Federal RePORTER (Alpha)

http://FederalRePORTER.nih.gov

OER Office of Data Analysis Tools and Systems

<u> Federal RePORTER</u>







CORIELL INSTITUTE

FOR MEDICAL RESEARCH

Resources for the 3 R's Alissa M. Resch, Ph.D.

September 24, 2015



Coriell Institute



Coriell Institute for Medical Research, founded in 1953 and based in Camden, New Jersey, is an independent non-profit research center dedicated to the study of the human genome. Expert staff and pioneering programs in the fields of personalized medicine, cell biology, cytogenetics, genotyping, and biobanking drive our mission.





Overview of Coriell



- Basic biomedical research institute, committed to genetic research, biobanking, and education
- Home of the *Coriell Biorepositories* ranks among the world's largest collection of living human cells and genomic DNA for use in research
- Funded iPSC laboratory and stem cell biobank
- Expert staff and pioneering programs in the fields of personalized medicine, cell biology, cytogenetics, genotyping, and biobanking
- ISO9001-2008 certified (Quality Management System)



Coriell Recognition

- "Pioneers in the field of personalized medicine"
 - Health and Human Services
- Top 10 "Research to Watch"
 - MIT Technology Review
- "Leading by example"
 - Nature Magazine
- "Transformations: 50 things that will change Philadelphia in 2015"
 - Philadelphia Business Journal



Coriell Biorepositories



Repository Highlights


Since 1964, NIH funding has supported Coriell Repository activities





- \$48.4M in federally-sponsored contract awards in the last five years
- Originally executed in 1972, the NIGMS-Coriell contract is the longest uninterrupted contract at NIH





Repository Collections and Services

Government Repositories

NEI/AREDS

NHGRI

NIA

NIGMS

NINDS

Non-Profit Repositories

ADA

CHDI

Coriell-Owned Repositories

Autism Resource

IPBIR

Custom Services

Cell culture

Genotyping

Molecular biology

Stem cell

Safe Storage

Fail-safe

Short-term

Long-term

Testing Services

DNA fingerprinting

Karyotyping

Pluritest

QPCR



Collection Types in the Repository

Funding Agency/Organization	Grant, Contract or Collection	Brief Overview					
National Institute of General Medical Science (NIGMS)	1U42GM115336-01	Standard-setting collection used for disease gene discovery, with emphasis on Mendelian diseases and human populations, plus animal cell lines and DNA from dog, cow and hamster					
National Institute of Neurological Disorder and Stoke (NINDS)	HHSN-271200800033C	Broad collection of human samples for study of neurological disorders, accompanied by rich phenotypic data					
National Human Genome Research Institute (NHGRI)	HHSN-268201100040C	Landmark collection of human population samples from the International HapMap and 1000 Genomes Projects					
National Institute on Aging (NIA)	HHSN-271201500003C	Diverse set of human and animal cell lines and DNA samples collected for aging studies, plus mouse ES cells and transgenic lines					
California Institute for Regenerative Medicine (CIRM)	IR1-06600	Largest publicly available human iPSC bank collected from individuals with diseases including autism, neurodevelopmental, eye, heart, and lung disorders					
New England Research Institutes (NERI)	U01 HL098188 Heart Disease Genetic Study	Collection of human samples used for study of congenital heart disease					
EMMES Corporation & National Eye Institute (NEI)	Age-Related Eye Disease Study (AREDS)	Human samples used to identify novel factors relevant to the pathogenesis, progression and response to treatment of a variety of retinal conditions					
Jackson Laboratories	JAX Collection	Collection of mouse embryos, sperm, and tissues, as well as human tumor samples					
Yerkes National Primate Research Center	Yerkes Primate Resource	Collection of viable cell cultures and DNA samples from primate <i>Pan troglodytes</i>					
Integrated Primate Biomaterials and Information Resource	IPBIR Repository	Collection of cell lines and DNA samples of known provenance with accompanying demographic, geographic and behavioral information for a variety of primate species					



NIA Adipose Stromal Cells Ames Dwarf Mouse Collection Mouse Embryonic Stem Cells Premature Aging Disorders Alzheimer Disease GRC Collection (BLSA) Longevity Collection Adolescent Study of Obesity **Animal Models of Aging** Differentiated Cell Types Apparently Healthy Controls Specially Characterized Fibroblasts More Diseases Genes **DNA Plates and Panels** About Mission and Organization How to Submit How to Order Ordering mESC - How to Order Additional Resources mESC Protocols

FAQ

Animal Models of Aging

Animal Models of Aging

- Order: Carnivora
 - Genus: Ailurus (panda)
 - Genus: Canis
 - Species: familiaris (dog)
- · Order: Cetartiodactyla
 - o Genus: Bos (cow)
 - · Genus: Muntiacus (muntjak)
 - · Genus: Sus (pig)
- Order: Lagomorpha
 - Genus: Oryctolagus (rabbit)
- Order Perissodactyla
 - Genus: Equus
 - Species: caballus (horse)
- Order: Primates
 - Genus: Callicebus (paraguayan titi)
 - Genus: Erythrocebus (patas monkey)
 - Genus: Lagothrix (Woolly monkey)
 - · Genus: Lemur
 - Species: catta (ring-tailed lemur)
 - · Genus: Macaca
 - Species: mulatta (rhesus)
 - Species: nemestrina (pigtailed macaque)
 - Species: nigra (Celebes ape)
 - Genus: Papio
 - Genus: Saguinus
 - Species: fuscicollis (white-lipped tamarin)
 - Species: labiatus (red-bellied tamarin)
 - Genus: Saimiri (squirrel monkey)
- Order: Rodentia
 - Genus: Cricetulus (Chinese hamster)
 - · Genus: Mesocricetus (golden Syrian hamster)
 - Genus: Mus (mouse)
 - o Genus: Mus (Ames mouse)
 - Genus: Peromyscus (California mouse)
 - · Genus: Peromyscus (deer mouse)
 - Genus: Peromyscus (oldfield mouse)
 - Genus: Peromyscus (white-footed mouse)
 - Genus: Rattus (rat)
- Order: Testudines
 - Genus: Geochelone (Galapagos tortoise)



Other Important Partnerships

- National Cancer Institute (NCI, NIH)
- National Science Foundation (NSF)
- Centers for Disease Control and Prevention (CDC)
- US Immunodeficiency Network (USIDNET)
- CHDI Foundation (Huntington's Disease Foundation)
- American Diabetes Foundation
- Autism Research Resource
- Wistar Institute





Sample Types in the Repository

- Genomic DNA
- Total RNA
- Saliva
- Frozen whole blood
- Plasma
- Serum
- Urine
- Cerebrospinal fluid
- Normal & tumor tissue
- Histology slides
- Human transformed B-cells [LCLs]
- Cultured human fibroblasts
- Human PBMCs
- Tumor cell lines
- Animal cell lines: cow, dog, hamster
- Mouse/human hybridoma cell lines that produce antibodies
- Polyclonal & monoclonal antibodies
- Purified proteins
- Plasmid "mini-genes" [Huntington's Disease Molecular Tool Box]
- Mouse ESCs and human iPSCs






Biobanking Logistics Capabilities

- Enhanced capabilities in inventory management
 - Inventory management of main and fail-safe storage locations with real-time RIMS database
- State-of-the-art freezers and cryogenic tanks equipped with alarms, monitors and sensors
 - -80°C ultra-low freezers
 - Liquid nitrogen (LN2) and liquid nitrogen vapor (VN2) cryogenic tanks
 - In-house and remote storage facilities equipped with limited-access and break-in security system



Stem Cell and Induced Pluripotent Stem Cell Lines

- Largest collection of iPSCs for reprogramming, expansion and cryopreservation
- Comprehensive quality control
- Characterization of iPSC lines
 - Embryoid body formation, Surface antigen testing, PluriTest (gene expression), G-banding karyotype analysis, Genotyping microarrays
- Disease-in-a-dish research
- Growth and characterization of mouse embryonic stem cells (mESCs)





The CIRM Stem Cell Repository

 California Institute for Regenerative Medicine (CIRM) was established to accelerate stem cell research in California by the establishment of a \$3 billion fund approved by taxpayers.



- This initiative will establish a state-of-the-art iPSC bank in California that will be broadly accessible by researchers worldwide.
- Tissue samples collected from patients suffering from Alzheimer's disease, autism spectrum disorders, liver diseases, cardiovascular diseases, neurodevelopmental disabilities such as cerebral palsy and infantile epilepsy, diseases of the eye, or respiratory diseases.
- Coriell collaborating with Cellular Dynamics International (CDI) to create and distribute 3 induced pluripotent stem cell (iPSC) lines for each of 3,000 healthy and diseased donors.




 Coriell Institute ~\$10 million by CIRM to set up and bank the iPSC lines.



Coriell Research Services



Coriell Cell Culturing Services




- Isolation and cryopreservation of peripheral blood mononuclear cells (PBMC)
- EBV-transformation of PBMCs for establishing immortalized lymphoblastoid lines
- Establishment of primary fibroblasts and differentiated cell lines from biopsy
- Growth of cell lines for isolation of DNA and RNA
- Expansion of cell lines for distribution, stock maintenance, molecular and cytogenetic analysis



Coriell Molecular Biology Services

- Genomic DNA, total RNA and miRNA isolation from blood, cells and tissues
- Large scale propagation of transfection-ready plasmid DNA
- Genotyping with highly polymorphic microsatellite markers using multiplex fluorescent PCR; pedigree verification and cell line authentication
- Hemoglobin testing of biofluids (e.g., plasma, serum)

 Mycoplasma testing by Real Time PCR assay





Coriell Genotyping and Microarray Center

- One of the largest microarray facilities in the nation offering genome-wide genotyping
- High-throughput platforms
- CLIA certified in 50 states
- Affymetrix SNP 6.0 and DMET Plus[®] arrays
- mRNA and miRNA expression profiling
- Copy number variation analysis
- Custom genotyping panels
- Instrument capacity for 2000-3000 samples per month
- Ion Torrent Targeted DNA/RNA Sequencing








Sequencing Options for Multiple Organisms

Affymetrix offers over 6 dozen types of arrays:


- Human U133 array
- Mouse 430 array
- Rat array
- Drosophila gene array
- E. coli array
- P. aeruginosa array






Cytogenetics

- G-banded karyotype analysis
- Analysis of copy number variation and loss of heterozygosity using Affymetrix Genome-Wide Human SNP Array 6.0
- FISH analysis including probe design, labeling, purification and validation
- Application of cytogenetic and cytogenomic services for stem cell studies and transgenics quality control






How to Order Samples



Access Coriell's online catalog → https://catalog.coriell.org





Instructions for Ordering Samples

- Determine which repository contains sample(s) of interest
- Click on sample ID to retrieve information about sample
- Fill out required paperwork: 1) Statement of Research Intent and 2) Material Transfer Agreement (MTA)/Assurance Form
- Place order through Coriell's online catalog, or contact Customer Service Department by phone:
 - Call (800) 752-3805 (USA)
 - Call +1 (856) 757-4848 (World)
 - Email customerservice@coriell.org



Sample Pricing



Sample Pricing

- Sample prices vary, depending on which repository sample is ordered from
- Click on sample ID to retrieve information about sample price
- Product types include:
 - Live or frozen cell cultures
 - Cell pellets
 - DNA aliquots
 - DNA panels
 - DNA plates



Price by Contract





HOME BROWSE/SEARCH BIOREPOSITORIES SERVICES SUPPORT CONTACT US Search.... Q



ILWKI

Pricing Information


Product	Price
DNA (50 µg aliquot)	\$55
Cell Lines	\$85
Fosmid Clone, Glycerol Stock	\$75
96-Well Plate ¹	\$8000
HapMap Panel (50µg DNA per sample, 90 sample panel)	\$4950
1,000 Genomes Panel (2µg DNA per sample, 100 or more samples per panel)	\$1000
1,000 Genomes Panel (2µg DNA per sample, 99 or less samples per panel)	\$900
¹ The 96-well plates for NHGRI contain 90 unique samples with 5 samples used twice on the plate. Each well contain	ains 50 µg of DNA.

NHGRI Sample Repository Cell Line Pricing Policy

The fee for a T25 flask of cells is \$85. When an order for a large number of cell cultures is placed at one time, the fee for each of the first 250 cultures is \$85 and the fee for each additional culture is \$25. Purchasers may arrange to take delivery on these cultures on several different dates. The Repository is designed to provide only seed cultures and will not provide more than one flask of each culture requested per order. See ordering instructions for more information.



Detailed Sample Information





Thank You!



Uses for These Resources

- Identify similar or complimentary models
- Identify refinements
- Find collaborators
- Find subject matter experts
- Reduce use of live animals
- Reduce costs for research



Now: Type your questions into the chat box on GoToMeeting dashboard.

Later: email your questions to OLAWDPE@mail.nih.gov



Does OLAW expect investigators to use NIH RePORTER and the Coriell's resources exclusively?



No, while NIH produces RePORTER and supports many of the Coriell's repositories, use of these resources is optional. As we learned from Brian and Alissa, these resources offer valuable information that may be useful in identifying collaborations, finding subject matter expertise, and obtaining samples as an alternative to the use of live animals.

RePORTER and Coriell are examples of the types of resources that may be used to implement the 3Rs. There are many other ways to find this type of information including literature searches as we highlighted in the OLAW June 2014 webinar.



Would searching NIH RePORTER or Federal RePORTER qualify as an alternative search to meet Animal Welfare Act Regulation requirements?



Maybe. NIH and Federal RePORTER provide valuable information about research models and NIH RePORTER includes publications resulting from NIH funded research. Their usefulness in finding alternatives to painful or distressful procedures has not been evaluated.

It's an interesting idea that may be best explored with the help of your institution's librarian. Ultimately, it is the effectiveness of the search that matters.

What other features do RePORT and RePORTER offer that might be of interest to investigators?



RePORT offers:

- NIH Awards by Location and Organization tool, which can simplify the process of finding NIH-supported projects in particular states, at particular organizations, or in particular types of institutions(like schools of veterinary medicine).
- NIH Data Book, which summarizes trends in research funding and success rates
- NIH Funding Facts, quick access to statistics from the NIH Data Book and annual reports produced by the NIH OER's Division of Information Services.

Must an investigator have an NIH grant to procure samples from Coriell?



No. Coriell's Biorepositories are available for purchase regardless of funding arrangements. While procurement requirements may vary across collections, investigators must at minimum complete and submit a Material Transfer Agreement form and a Statement of Research Intent.

Must IACUCs review requests when investigators obtain items from Coriell?



No. IACUC review is not required when animal tissue or other materials are obtained from repositories like Coriell.

Some institutions may have animal biosecurity policies that require review of biological products to be administered to animals or that are classified as biohazards.





OLAW Online Seminar Q & A with OLAW December 3, 2015